Navigation Links
Transition Therapeutics Announces Milestone Payment from Elan
Date:12/24/2007

TORONTO, Dec. 24 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), announced today that the Company will receive a US$5million milestone payment under its global collaboration agreement with a subsidiary of Elan Corporation, plc ("Elan") (NYSE: ELN). The milestone payment was triggered by the initiation of a Phase 2 clinical study of Alzheimer's disease drug candidate, ELND005 (AZD-103), which was jointly announced by Transition and Elan on December 21, 2007.

In connection with the enrolment of the first patient in the Phase 2 clinical study, Transition will issue the former shareholders of Ellipsis Neurotherapeutics Inc. ("ENI") 174,123 Transition common shares at a price of $10.86 per share, which represents the weighted average trading price for the last five trading days. The financial terms associated with the acquisition of ENI were previously disclosed in a press release dated March 13, 2006.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Prime Therapeutics Receives TIPPS Certification
7. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , ... August 23, 2017 , ... Drs. Steven White ... in Cornelius, NC. By taking advantage of this offer, valued at more than ... regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening procedure. ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... to prove the safety and efficacy of HBOT in treating and helping to ... US, points to research showing the similarities of the wounds to the brain ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the winners ... Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs were ... by a points system based on the total number of awards won in the IBAs ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., a ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . The ... comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s fifth ...
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine ... nationally that earned the designation of High Performing Hospitals by U.S. News & World ... indicates a hospital was significantly better than the national average in a given ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology: